Inhibikase Therapeutics, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Summary of Stock Options Activity

The following is a summary of option activity under the 2011 Plan and the 2020 Plan:


	Number of Shares		Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (In Years)
Outstanding at December 31, 2018		2,822,796	$	1.01		8.19
Granted		546,348		5.57		5.65
Exercised		—		—		—
Forfeited		—		—		—
Cancelled		—		—		—

Outstanding at December 31, 2019		3,369,144		1.75		7.78
Granted		227,300		10.00		6.98
Exercised		—		—		—
Forfeited		—		—		—
Cancelled		—		—		—

Outstanding at December 31, 2020		3,596,444		2.27		7.73

Exercisable at December 31, 2020		3,274,444		1.68		7.84

Vested or expected to vest at December 31, 2020		3,596,444		2.27		7.73

Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options

The weighted-average fair values of options granted in the years ended December 31, 2020 and 2019 were $6.45 and $3.02, per share, respectively, and were calculated using the following estimated assumptions:


	Year ended December 31,
	2020			2019
Weighted-average risk-free interest rate		0.32	%		1.79	%
Expected dividend yield		0.00	%		0.00	%
Expected volatility		87.63	%		71.84	%
Expected terms		4.44 years			4.14 years

Summary of Stock Compensation Expense for Employees and Nonemployees by Function

The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees:


	Three Months Ended March 31,
	2021		2020
Research and development	$	368,495	$	65,020
Selling, general and administrative		222,629		74,738

Total stock-based compensation expense	$	591,124	$	139,758

The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees:


	Year ended December 31,
	2020		2019
Research and development	$	261,492	$	268,751
Selling, general and administrative		312,203		1,167,857

Total stock-based compensation expense	$	573,695	$	1,436,608